VistaGen Therapeutics, Inc.(VTGN)

Description: VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary new chemical entities (NCEs) for internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and liver cells derived from hPSC technology. The company is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. It has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. The company also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

---

Keywords: Biopharmaceutical Disease Health Sciences Drug Discovery Clinical Trial Pharmaceutical Sciences Disorders Clinical Development Regenerative Medicine Mental Health In Vitro Metabolism Clinical Pharmacology Major Depressive Disorder Antidepressants Cartilage Depressive Disorder Drug Metabolism Chemical Entities Treatment Of Major Depressive Disorder Prodrug Nmda Receptor Antagonists Potential Commercial Applications Response

---

Home Page: www.vistagen.com

VTGN Technical Analysis

343 Allerton Avenue
South San Francisco, CA 94080
United States
Phone: 650 577 3600

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)